tag:blogger.com,1999:blog-7857054149675424609.post3599592262290729161..comments2024-02-24T08:58:08.581+00:00Comments on RNAi Therapeutics: RXi Pharmaceuticals Appoints New CEO in Attempt to Become a Clinical-Stage CompanyDirk Hausseckerhttp://www.blogger.com/profile/18320439857875629714noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-7857054149675424609.post-66776584191332853422009-11-10T15:54:13.874+00:002009-11-10T15:54:13.874+00:00Hi Martin- It almost seems natural that at differe...Hi Martin- It almost seems natural that at different stages of a company you require different managements. I feel that this was also the case for Rosetta and that getting a person with more commercial experience in cancer Dx was the right move, although a year or two earlier would have made the transition smoother. I’m curious whether the new CEO will continue to place this heavy bet on the Dirk Hausseckerhttps://www.blogger.com/profile/18320439857875629714noreply@blogger.comtag:blogger.com,1999:blog-7857054149675424609.post-28497965843007708202009-11-09T09:42:25.606+00:002009-11-09T09:42:25.606+00:00Speaking of new CEOs, it is also noteworthy that R...Speaking of new CEOs, it is also noteworthy that Rosetta Genomics appointed a new CEO last week.<br /><br />Prior to being appointed CEO of Rosetta, Ken Berlin (45) served as worldwide General Manager at cellular and molecular cancer diagnostics developer Veridex, LLC, a Johnson & Johnson company.<br /><br />This move has to be welcomed by Rosetta's shareholders, who often perceived the Anonymousnoreply@blogger.com